FLT3 inhibitors and hematopoietic cell transplantation prolong survival in patients with FLT3-ITD-positive AML. Matsukawa T, Onozawa M, Kondo T, Kanaya M, et al. Ann Hematol 2024;103:5333-5340.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Matsukawa T, Onozawa M, Kondo T, Kanaya M, et al. FLT3 inhibitors and hematopoietic cell transplantation prolong survival in patients with FLT3-ITD-positive AML. Ann Hematol 2024;103:5333-5340.
PMID: 39614924